Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis

December 15, 2020

View Press Release Corporate presentation Contact us
Previous